Developer docs
API playgroundTry for free, no card

Search company profiles

Curetis

Full company profile

uuid0006536

Namestring
Curetis
Legal namestring
Curetis GmbH
Websiteurl
curetis.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Curetis GmbH is a Germany-based molecular diagnostics company that develops and commercializes the Unyvero Platform for syndromic testing of severe infectious diseases. The platform integrates multiplex PCR amplification with microarray hybridization and melting-curve analysis on single-use application cartridges, enabling simultaneous detection of pathogens and antibiotic resistance markers from native clinical samples in under five hours with approximately two minutes of hands-on time. The product set comprises the Unyvero A50 Analyzer (a two-cartridge random-access processor), the L4 Lysator for sample preparation, the C8 Cockpit for run control and data management, and a menu of application-specific cartridges including panels for bloodstream, respiratory, and implant and tissue infections.

The company's commercial model is a two-stream hardware-plus-consumable setup: one-time placement of the A50 system and recurring sales of single-use application cartridges priced on a quote basis. All sales are executed through third-party distribution rather than direct hospital contracts; A. Menarini Diagnostics entities serve as the exclusive distributor in eight Western European markets (Austria, France, Germany, Greece, Italy, Portugal, Spain, and the UK), supplemented by ten independent regional distributors across Eastern Europe, the Gulf, Egypt, and Latin America, for a stated footprint of 18 countries. Curetis targets hospital and clinical microbiology laboratories seeking faster, more comprehensive alternatives to culture-based diagnostics, particularly for culture-negative infections and antimicrobial resistance guidance.

Curetis was originally incorporated as a Dutch public company and was historically listed on Euronext Amsterdam (ams:CURE). The current operating entity, Curetis GmbH, is registered in Holzgerlingen, Germany, with 51–100 employees and Managing Directors Siew Hwa Ong, PhD and MengHan Kuok, PhD. Cumulative disclosed funding totals approximately $98 million across seven rounds from 2009 to 2019, with the most recent rounds led by Yorkville Advisors and the European Investment Bank. The company and product trademarks are registered in the EU, Switzerland, and the US.

Short descriptiontext

Curetis GmbH is a Germany-based molecular diagnostics company that commercializes the Unyvero Platform, a multiplex PCR and microarray system delivering syndromic pathogen and resistance marker detection in under five hours for hospital and clinical laboratories across 18 countries via distributor partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHolzgerlingen, Germany
HQ citystring
Holzgerlingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, syndromic testing, multiplex PCR, infectious disease detection, antibiotic resistance testing
Industry3 codes
PRIMARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Unyvero System Hardware
TypeHardware Sales
Description

Sale of the Unyvero System hardware including the A50 Analyzer, L4 Lysator, and C8 Cockpit components for molecular diagnostic testing in clinical laboratories.

curetis.com
2Application-Specific Cartridges
TypeOne Time License
Description

Sale of application-specific Unyvero cartridges for different clinical syndromes (e.g., Implant & Tissue Infection panel). Cartridges contain all components required for DNA isolation, amplification, and detection.

curetis.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Unyvero
Description

Rapid molecular diagnostic solution with broad coverage of pathogens and resistance markers. The Unyvero Platform consists of the Unyvero System and Application-specific Unyvero Cartridges.

curetis.com
Core offering1 text field

Curetis develops and commercializes the Unyvero Platform, a molecular diagnostic system for syndromic testing of severe infectious diseases. The platform uses multiplex PCR and microarray hybridization to simultaneously detect pathogens and antibiotic resistance markers from clinical samples in under 5 hours, and is sold as integrated hardware (A50 Analyzer, L4 Lysator, C8 Cockpit) paired with application-specific cartridges targeting major clinical syndromes such as bloodstream, respiratory, and implant and tissue infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results delivered in under 5 hours with only 2 minutes hands-on time
+2 more records
Product overview1 text field

Curetis offers the Unyvero Platform, a rapid molecular diagnostic system for syndromic testing of severe infections. The platform consists of the Unyvero A50 Analyzer (which processes two cartridges independently with full random-access capabilities), the Unyvero C8 Cockpit (for controlling the system and managing results), and the Unyvero L4 Lysator (for sample preparation). Application-specific Unyvero Cartridges are used with the system to provide simultaneous testing for pathogens and resistance markers across major clinical syndromes, delivering results in under 5 hours with only 2 minutes of hands-on time. The cartridges utilize powerful multiplex PCR technology followed by microarray hybridization for broad panel detection.

Product and service6 records
1Unyvero Platform
CategoryMolecular diagnostic platform
Description

Rapid molecular diagnostic platform combining the Unyvero System hardware with application-specific cartridges, utilizing multiplex PCR technology to detect microorganisms and antibiotic resistance markers from sample-to-answer in under 5 hours. Intended for hospital and clinical laboratories performing syndromic infectious disease testing.

2Unyvero A50 Analyzer
CategoryDiagnostic instrument hardware
Description

Central processing unit of the Unyvero System that runs two application cartridges independently with full random-access capability, delivering results in less than 5 hours with only 2 minutes of hands-on time. Designed for clinical laboratory use.

3Unyvero L4 Lysator
CategoryDiagnostic instrument hardware
Description

Sample preparation device that lyses a wide variety of clinical samples, including difficult native specimens, preparing them for cartridge-based molecular analysis on the Unyvero System.

4Unyvero C8 Cockpit
CategoryDiagnostic instrument hardware
Description

Control interface of the Unyvero System that manages the testing process, displays results, and supports storage and sharing of diagnostic data from the Unyvero workflow.

5Unyvero Application Cartridge
CategoryDiagnostic consumables / cartridges
Description

Application-specific disposable cartridges that contain all reagents required for DNA isolation, multiplex PCR amplification, and microarray hybridization detection on the Unyvero System, supporting broad syndromic testing panels for major clinical syndromes.

6Unyvero Implant & Tissue Infection (ITI) Panel
CategoryDiagnostic consumables / cartridges
Description

Application cartridge panel for the Unyvero System that detects pathogens and antibiotic resistance markers associated with implant and tissue infections, with high specificity in distinguishing between Streptococci and Abiotrophia species.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A. Menarini GmbH serves as the exclusive distributor for the Unyvero System and cartridges in Austria, operating from Wien.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A. MENARINI Diagnostics France S.A.R.L. distributes Unyvero products in France from their office in Rungis.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A. MENARINI DIAGNOSTICS DEUTSCHLAND, a division of BERLIN-CHEMIE AG, distributes Unyvero products in Germany from Berlin.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

MENARINI diagnostics SA serves as distributor for Unyvero products in Greece, operating from Athens.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A.Menarini Diagnostics S.r.L. distributes Unyvero products in Italy from their operative offices in Bagno a Ripoli (Florence).

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Menarini Diagnósticos, Lda distributes Unyvero products in Portugal from Paço de Arcos.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A.Menarini Diagnostics distributes Unyvero products in Spain from Badalona near Barcelona.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

A.Menarini Diagnostics Ltd. distributes Unyvero products in the UK from Winnersh-Wokingham.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Annar Diagnóstica Import SAS distributes Unyvero products in Colombia from Bogotá.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Quantum Eesti AS distributes Unyvero products in Estonia from Räni, near Tartu.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Eruditio - Sensuum sprl distributes Unyvero products in Belgium, Netherlands, and Luxembourg from Waterloo, Belgium.

12Future Horizon Scientific (Egypt)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Future Horizon Scientific distributes Unyvero products in Egypt from Cairo.

curetis.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

KEIS (Kosova Export Import Supply Pharmaceutical) Sh.P.K. distributes Unyvero products in Kosovo from Prishtine.

14Advanced Technology Company (Kuwait)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Advanced Technology Company distributes Unyvero products in Kuwait from Hawalli.

curetis.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Biomedical Innovations Limited Co. distributes Unyvero products in Saudi Arabia from Riyadh.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

NoaTech UAB distributes Unyvero products in Lithuania and Latvia from Druskininkai, Lithuania.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Synttergy Consult distributes Unyvero products in Romania from Bucharest.

18AKOMED d.o.o. (Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, Croatia)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

AKOMED d.o.o. distributes Unyvero products across multiple Balkan countries including Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, and Croatia from Belgrade.

curetis.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curetis

Molecular Diagnosticscuretis.com

Curetis GmbH is a Germany-based molecular diagnostics company that commercializes the Unyvero Platform, a multiplex PCR and microarray system delivering syndromic pathogen and resistance marker detection in under five hours for hospital and clinical laboratories across 18 countries via distributor partners.

What Curetis does

Curetis GmbH is a Germany-based molecular diagnostics company that develops and commercializes the Unyvero Platform for syndromic testing of severe infectious diseases. The platform integrates multiplex PCR amplification with microarray hybridization and melting-curve analysis on single-use application cartridges, enabling simultaneous detection of pathogens and antibiotic resistance markers from native clinical samples in under five hours with approximately two minutes of hands-on time. The product set comprises the Unyvero A50 Analyzer (a two-cartridge random-access processor), the L4 Lysator for sample preparation, the C8 Cockpit for run control and data management, and a menu of application-specific cartridges including panels for bloodstream, respiratory, and implant and tissue infections.

The company's commercial model is a two-stream hardware-plus-consumable setup: one-time placement of the A50 system and recurring sales of single-use application cartridges priced on a quote basis. All sales are executed through third-party distribution rather than direct hospital contracts; A. Menarini Diagnostics entities serve as the exclusive distributor in eight Western European markets (Austria, France, Germany, Greece, Italy, Portugal, Spain, and the UK), supplemented by ten independent regional distributors across Eastern Europe, the Gulf, Egypt, and Latin America, for a stated footprint of 18 countries. Curetis targets hospital and clinical microbiology laboratories seeking faster, more comprehensive alternatives to culture-based diagnostics, particularly for culture-negative infections and antimicrobial resistance guidance.

Curetis was originally incorporated as a Dutch public company and was historically listed on Euronext Amsterdam (ams:CURE). The current operating entity, Curetis GmbH, is registered in Holzgerlingen, Germany, with 51–100 employees and Managing Directors Siew Hwa Ong, PhD and MengHan Kuok, PhD. Cumulative disclosed funding totals approximately $98 million across seven rounds from 2009 to 2019, with the most recent rounds led by Yorkville Advisors and the European Investment Bank. The company and product trademarks are registered in the EU, Switzerland, and the US.

Curetis firmographics

Firmographics
Name
Curetis
Legal name
Curetis GmbH
Website
https://curetis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Curetis GmbH is a Germany-based molecular diagnostics company that commercializes the Unyvero Platform, a multiplex PCR and microarray system delivering syndromic pathogen and resistance marker detection in under five hours for hospital and clinical laboratories across 18 countries via distributor partners.
Ownership category
akta.pro rank

Curetis industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAD
Hematology POCT (CBC/hemoglobin/hematocrit)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Molecular diagnostics
  • Syndromic testing
  • Multiplex PCR
  • Infectious disease detection
  • Antibiotic resistance testing

Where Curetis is headquartered

Location

Headquarters

HQ city
Holzgerlingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Curetis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Unyvero System Hardware: Sale of the Unyvero System hardware including the A50 Analyzer, L4 Lysator, and C8 Cockpit components for molecular diagnostic testing in clinical laboratories.
  2. Application-Specific Cartridges: Sale of application-specific Unyvero cartridges for different clinical syndromes (e.g., Implant & Tissue Infection panel). Cartridges contain all components required for DNA isolation, amplification, and detection.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Curetis product offering

Product offering

Core offering

Curetis develops and commercializes the Unyvero Platform, a molecular diagnostic system for syndromic testing of severe infectious diseases. The platform uses multiplex PCR and microarray hybridization to simultaneously detect pathogens and antibiotic resistance markers from clinical samples in under 5 hours, and is sold as integrated hardware (A50 Analyzer, L4 Lysator, C8 Cockpit) paired with application-specific cartridges targeting major clinical syndromes such as bloodstream, respiratory, and implant and tissue infections.

Product overview

Curetis offers the Unyvero Platform, a rapid molecular diagnostic system for syndromic testing of severe infections. The platform consists of the Unyvero A50 Analyzer (which processes two cartridges independently with full random-access capabilities), the Unyvero C8 Cockpit (for controlling the system and managing results), and the Unyvero L4 Lysator (for sample preparation). Application-specific Unyvero Cartridges are used with the system to provide simultaneous testing for pathogens and resistance markers across major clinical syndromes, delivering results in under 5 hours with only 2 minutes of hands-on time. The cartridges utilize powerful multiplex PCR technology followed by microarray hybridization for broad panel detection.

Differentiator

Problem solved

Functional benefit

Brands

  • Unyvero: Rapid molecular diagnostic solution with broad coverage of pathogens and resistance markers. The Unyvero Platform consists of the Unyvero System and Application-specific Unyvero Cartridges.

Products and services

  • Unyvero Platform Rapid molecular diagnostic platform combining the Unyvero System hardware with application-specific cartridges, utilizing multiplex PCR technology to detect microorganisms and antibiotic resistance markers from sample-to-answer in under 5 hours. Intended for hospital and clinical laboratories performing syndromic infectious disease testing.
  • Unyvero A50 Analyzer Central processing unit of the Unyvero System that runs two application cartridges independently with full random-access capability, delivering results in less than 5 hours with only 2 minutes of hands-on time. Designed for clinical laboratory use.
  • Unyvero L4 Lysator Sample preparation device that lyses a wide variety of clinical samples, including difficult native specimens, preparing them for cartridge-based molecular analysis on the Unyvero System.
  • Unyvero C8 Cockpit Control interface of the Unyvero System that manages the testing process, displays results, and supports storage and sharing of diagnostic data from the Unyvero workflow.
  • Unyvero Application Cartridge Application-specific disposable cartridges that contain all reagents required for DNA isolation, multiplex PCR amplification, and microarray hybridization detection on the Unyvero System, supporting broad syndromic testing panels for major clinical syndromes.
  • Unyvero Implant & Tissue Infection (ITI) Panel Application cartridge panel for the Unyvero System that detects pathogens and antibiotic resistance markers associated with implant and tissue infections, with high specificity in distinguishing between Streptococci and Abiotrophia species.

Quantifiable outcome

  • Results delivered in under 5 hours with only 2 minutes hands-on time
  • +2 more outcomes

Companies that use Curetis

Customer profile

Segments1 record

Ideal customer profiles1 record

Curetis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Curetis partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core and regional.

  • A. Menarini Diagnostics (Austria)coreChannel Partner/ Reseller/ DistributorA. Menarini GmbH serves as the exclusive distributor for the Unyvero System and cartridges in Austria, operating from Wien.
  • A. Menarini Diagnostics (France)coreChannel Partner/ Reseller/ DistributorA. MENARINI Diagnostics France S.A.R.L. distributes Unyvero products in France from their office in Rungis.
  • A. Menarini Diagnostics (Germany)coreChannel Partner/ Reseller/ DistributorA. MENARINI DIAGNOSTICS DEUTSCHLAND, a division of BERLIN-CHEMIE AG, distributes Unyvero products in Germany from Berlin.
  • A. Menarini Diagnostics (Greece)coreChannel Partner/ Reseller/ DistributorMENARINI diagnostics SA serves as distributor for Unyvero products in Greece, operating from Athens.
  • A. Menarini Diagnostics (Italy)coreChannel Partner/ Reseller/ DistributorA.Menarini Diagnostics S.r.L. distributes Unyvero products in Italy from their operative offices in Bagno a Ripoli (Florence).
  • A. Menarini Diagnostics (Portugal)coreChannel Partner/ Reseller/ DistributorMenarini Diagnósticos, Lda distributes Unyvero products in Portugal from Paço de Arcos.
  • A. Menarini Diagnostics (Spain)coreChannel Partner/ Reseller/ DistributorA.Menarini Diagnostics distributes Unyvero products in Spain from Badalona near Barcelona.
  • A. Menarini Diagnostics (United Kingdom)coreChannel Partner/ Reseller/ DistributorA.Menarini Diagnostics Ltd. distributes Unyvero products in the UK from Winnersh-Wokingham.
  • ANNAR Health Technologies (Colombia)regionalChannel Partner/ Reseller/ DistributorAnnar Diagnóstica Import SAS distributes Unyvero products in Colombia from Bogotá.
  • Quantum Eesti AS (Estonia)regionalChannel Partner/ Reseller/ DistributorQuantum Eesti AS distributes Unyvero products in Estonia from Räni, near Tartu.
  • Eruditio - Sensuum sprl (Belgium, Netherlands, Luxembourg)regionalChannel Partner/ Reseller/ DistributorEruditio - Sensuum sprl distributes Unyvero products in Belgium, Netherlands, and Luxembourg from Waterloo, Belgium.
  • Future Horizon Scientific (Egypt)regionalChannel Partner/ Reseller/ DistributorFuture Horizon Scientific distributes Unyvero products in Egypt from Cairo.
  • KEIS (Kosovo)regionalChannel Partner/ Reseller/ DistributorKEIS (Kosova Export Import Supply Pharmaceutical) Sh.P.K. distributes Unyvero products in Kosovo from Prishtine.
  • Advanced Technology Company (Kuwait)regionalChannel Partner/ Reseller/ DistributorAdvanced Technology Company distributes Unyvero products in Kuwait from Hawalli.
  • Biomedical Innovations Limited Co. (Saudi Arabia)regionalChannel Partner/ Reseller/ DistributorBiomedical Innovations Limited Co. distributes Unyvero products in Saudi Arabia from Riyadh.
  • NoaTech UAB (Lithuania, Latvia)regionalChannel Partner/ Reseller/ DistributorNoaTech UAB distributes Unyvero products in Lithuania and Latvia from Druskininkai, Lithuania.
  • Synttergy Consult (Romania)regionalChannel Partner/ Reseller/ DistributorSynttergy Consult distributes Unyvero products in Romania from Bucharest.
  • AKOMED d.o.o. (Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, Croatia)regionalChannel Partner/ Reseller/ DistributorAKOMED d.o.o. distributes Unyvero products across multiple Balkan countries including Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, and Croatia from Belgrade.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Curetis competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Curetis social profiles

Digital presence

Curetis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curetis leadership team

Management profile

Number of profiles

Profiles5 records

Curetis funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curetis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curetis

What does Curetis do?

Curetis develops and commercializes the Unyvero Platform, a molecular diagnostic system for syndromic testing of severe infectious diseases. The platform uses multiplex PCR and microarray hybridization to simultaneously detect pathogens and antibiotic resistance markers from clinical samples in under 5 hours, and is sold as integrated hardware (A50 Analyzer, L4 Lysator, C8 Cockpit) paired with application-specific cartridges targeting major clinical syndromes such as bloodstream, respiratory, and implant and tissue infections.

Is Curetis a public or private company?

Curetis is a private company. It is classified as unknown and is currently operating.

When was Curetis founded?

Curetis was founded in 2007. It employs 11 to 50 people.

Where is Curetis based?

Curetis is headquartered in Holzgerlingen, Germany, in the Europe region.

How does Curetis make money?

Two revenue lines are on record. Unyvero System Hardware is the primary driver. The others are application-Specific Cartridges.

Does Curetis have an API?

No public API is recorded for Curetis.

What industry is Curetis in?

Curetis's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAD, Hematology POCT (CBC/hemoglobin/hematocrit), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaWhy Is Penny Stock OpGen Trading Higher On Tuesday? - CapForce Inc (OTC:OPGN)OpGen Inc entered into a securities purchase agreement with private investor David Lazar to raise $3.0 million through the sale of Series E Convertible Preferred Stock, appointing Lazar as CEO and triggering the resignation of prior board members and the previous CEO. The company will utilize the proceeds to settle outstanding liabilities with the European Investment Bank and its subsidiary Curetis. This leadership change and debt restructuring occurred alongside a significant increase in trading volume for OpGen's shares.Benzinga500% Gain In Premarket Session - Here's Why Precision Medicine OpGen Stock Is Soaring - CapForce Inc (OTCOpGen Inc stock surged 578.6% to $2.28 in premarket trading following two SEC filings, with session volume of 14.9 million shares compared to the trailing 100-day average of 2.24 million. The precision medicine company received an advance payment of €750,000 related to the sale of Unyvero A50 systems by Curetis to a strategic partner, and separately raised $1 million through a Preferred Stock Purchase Agreement with an investor. OpGen stated it intends to use the advance payment to fund Curetis' and Ares Genetics' operations while negotiating the potential strategic transaction.GlobeNewswireOpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration AgreementCuretis GmbH signed an extended R&D collaboration agreement with FIND to develop an antimicrobial resistance assay and cartridge for low- and middle-income countries. The project budget is approximately $0.6 million, bringing total collaboration commitment to about $1.5 million. The development phase is expected to last about ten months.GlobeNewswireOpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 InstrumentsCuretis GmbH received a batch of ten Unyvero A30 C-Series instruments after final assembly and testing. The instruments incorporate improvements from prior B-Series testing and will be used for product development, clinical trials, and regulatory submissions. The company also upgraded its ten B-Series instruments to the latest standard.BioSpaceOpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration ProjectOpGen announced that its subsidiary Curetis met several milestones under a collaboration agreement with FIND as of end of 2022, triggering an undisclosed milestone payment. The milestones included DNA isolation and PCR demonstrations on the Unyvero A30 cartridge and a defined product requirements list. OpGen expects to complete remaining milestones by the second quarter of 2023.GlobeNewswireOpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration ProjectOpGen's subsidiary Curetis met several milestones in its FIND collaboration project by end of 2022, including DNA isolation and assay demonstrations. The completion triggered an undisclosed milestone payment. The company expects to finish remaining deliverables by Q2 2023 and pursue broader collaboration.BioSpaceOpGen Announces Successful Completion of Unyvero A30 Development MilestoneOpGen's subsidiary Curetis completed verification and validation and lifetime testing for the Unyvero A30 RQ platform instruments, meeting all criteria. The tests included over a million PCR cycles for the Peltier element. The company now plans to build series-ready instruments and begin clinical trials later in 2022.GlobeNewswireOpGen Appoints Albert Weber as Chief Financial OfficerOpGen appointed Albert Weber as CFO and Managing Director of Curetis GmbH, effective January 1, 2022. The company granted him 210,000 stock options under an inducement grant exception. Weber brings over 30 years of corporate finance experience from Epigenomics.BioSpaceOpGen Appoints Albert Weber as Chief Financial OfficerOpGen appointed Albert Weber as CFO and Managing Director of Curetis GmbH, effective January 1, 2022. The company granted him 210,000 stock options under an inducement grant exception. Weber brings over 30 years of corporate finance experience from Epigenomics.GlobeNewswireOpGen Wins Chinese NMPA Approval for the Curetis Unyvero SystemOpGen's subsidiary Curetis received NMPA approval for the Unyvero system as an IVD instrument in China. The pneumonia cartridge application is under review, with commercialization pending that approval. BCB has agreed to minimum purchases of 360 systems and 1.5 million cartridges over eight years.